442 related articles for article (PubMed ID: 30378141)
21. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
Feagan BG; Patel H; Colombel JF; Rubin DT; James A; Mody R; Lasch K
Aliment Pharmacol Ther; 2017 Jan; 45(2):264-275. PubMed ID: 27859410
[TBL] [Abstract][Full Text] [Related]
22. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
Dulai PS; Battat R; Barsky M; Nguyen NH; Ma C; Narula N; Mosli M; Vande Casteele N; Boland BS; Prokop L; Murad MH; D'Haens G; Feagan BG; Sandborn WJ; Jairath V; Singh S
Am J Gastroenterol; 2020 Jun; 115(6):885-894. PubMed ID: 32384283
[TBL] [Abstract][Full Text] [Related]
23. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
24. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
25. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
[TBL] [Abstract][Full Text] [Related]
26. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
Dulai PS; Singh S; Jairath V; Ma C; Narula N; Vande Casteele N; Peyrin-Biroulet L; Vermeire S; D'Haens G; Feagan BG; Sandborn WJ
Aliment Pharmacol Ther; 2020 Feb; 51(4):435-445. PubMed ID: 31755121
[TBL] [Abstract][Full Text] [Related]
28. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
Singh S; Murad MH; Fumery M; Dulai PS; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2179-2191.e6. PubMed ID: 31945470
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; López-Del Val A
Eur J Hosp Pharm; 2020 Nov; 27(6):355-360. PubMed ID: 33097619
[TBL] [Abstract][Full Text] [Related]
30. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
Danese S; Fiorino G; Peyrin-Biroulet L; Lucenteforte E; Virgili G; Moja L; Bonovas S
Ann Intern Med; 2014 May; 160(10):704-11. PubMed ID: 24842416
[TBL] [Abstract][Full Text] [Related]
31. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
Feagan BG; Reinisch W; Rutgeerts P; Sandborn WJ; Yan S; Eisenberg D; Bala M; Johanns J; Olson A; Hanauer SB
Am J Gastroenterol; 2007 Apr; 102(4):794-802. PubMed ID: 17324131
[TBL] [Abstract][Full Text] [Related]
32. Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
Peyrin-Biroulet L; Bossuyt P; Bettenworth D; Loftus EV; Anjie SI; D'Haens G; Saruta M; Arkkila P; Park H; Choi D; Kim DH; Reinisch W
Dig Dis Sci; 2024 May; 69(5):1808-1825. PubMed ID: 38499736
[TBL] [Abstract][Full Text] [Related]
33. Current and emerging biologics for ulcerative colitis.
Park SC; Jeen YT
Gut Liver; 2015 Jan; 9(1):18-27. PubMed ID: 25547087
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
36. Emerging treatments for ulcerative colitis: a systematic review.
Kokkinidis DG; Bosdelekidou EE; Iliopoulou SM; Tassos AG; Texakalidis PT; Economopoulos KP; Kousoulis AA
Scand J Gastroenterol; 2017 Sep; 52(9):923-931. PubMed ID: 28503977
[TBL] [Abstract][Full Text] [Related]
37. Biologic Therapy for Ulcerative Colitis.
Bhattacharya A; Osterman MT
Gastroenterol Clin North Am; 2020 Dec; 49(4):717-729. PubMed ID: 33121691
[TBL] [Abstract][Full Text] [Related]
38. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis.
Trigo-Vicente C; Gimeno-Ballester V; García-López S; López-Del Val A
Int J Clin Pharm; 2018 Dec; 40(6):1411-1419. PubMed ID: 30478492
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis.
Lu X; Jarrett J; Sadler S; Tan M; Dennis J; Jairath V
Int J Clin Pharm; 2023 Apr; 45(2):330-341. PubMed ID: 36484968
[TBL] [Abstract][Full Text] [Related]
40. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.
Stidham RW; Lee TC; Higgins PD; Deshpande AR; Sussman DA; Singal AG; Elmunzer BJ; Saini SD; Vijan S; Waljee AK
Aliment Pharmacol Ther; 2014 Apr; 39(7):660-71. PubMed ID: 24506179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
